|
Viral breakthrough in HBV treatment with nucleoside analogs may be due to noncompliance. |
 |
 |
|
EurekAlert: HBV DNA decreased in the ten patients who initially experienced a VBT, but who did not have confirmed VBT or GR, when the same drug regimen was maintained. Nine of these patients had undetectable HBV DNA at the most recent follow-up, a mean of 7 months after the initial VBT. These data suggest that nonadherence to medication may be a common cause of VBT. "Counseling patients with chronic hepatitis B on the importance of medication adherence, and confirming reemergence of the virus and genetic mutations that cause resistance, can help to avoid unnecessary changes to antiviral treatments," advised Dr. Lok.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
